| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1079: Fruquintinib for previously treated metastatic colorectal cancer |
|
Medicine details |
|
| Medicine name | fruquintinib (Fruzaqla®) |
| Formulation | 1 mg hard capsule, 5 mg hard capsule |
| Reference number | 4197 |
| Indication | For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy |
| Company | Takeda UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/06/2025 |
| NICE guidance | TA1079: Fruquintinib for previously treated metastatic colorectal cancer |